← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
CRANDELL KEITH
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001219039
Purchase history
- Companies traded
- 6
- Purchases · 12M
- 4
- Purchases · 24M
- 6
- Average purchase
- $17.9M
- Median purchase
- $16.1M
- Gross purchase value
- $107.3M
Companies: Kardigan, Inc. | Lyell Immunopharma, Inc. | Metsera, Inc. | Neumora Therapeutics, Inc. | Prime Medicine, Inc. | Seaport Therapeutics, Inc.
6 SEC accession(s) · 6 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-06-24 | Kardigan, Inc. | KARD | Director | 10% Owner | $20.0M | Open filing |
| 2026-05-04 | Seaport Therapeutics, Inc. | SPTX | 10% Owner | $19.8M | Open filing |
| 2026-03-09 | Lyell Immunopharma, Inc. | LYEL | 10% Owner | $12.5M | Open filing |
| 2025-10-29 | Neumora Therapeutics, Inc. | NMRA | 10% Owner | $5.0M | Open filing |
| 2025-08-01 | Prime Medicine, Inc. | PRME | 10% Owner | $10.0M | Open filing |
| 2025-02-03 | Metsera, Inc. | MTSR | 10% Owner | $40.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small Sample | 16.7% (1/6) | 100.0% (1/1) | +7.7% | +7.7% | +7.7% |
| 20D | 1Small Sample | 16.7% (1/6) | 0.0% (0/1) | -2.3% | -2.3% | -2.3% |
| 60D | 1Small Sample | 16.7% (1/6) | 0.0% (0/1) | -28.6% | -28.6% | -28.6% |
| 120D | 0No Data | 0.0% (0/4) | — | — | — | — |
Research patterns
- First purchase in 12M
- 4/4
- Large purchase ≥ $100k
- 6/6
- Cluster buying · 15D
- 6/6
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.